Amide-sulfamide modulators as effective anti-tumor metastatic agents targeting CXCR4/CXCL12 axis

被引:11
|
作者
Wu, Rui [1 ]
Yu, Wenyan [1 ]
Yao, Chuansheng [1 ]
Liang, Zhongxing [2 ]
Yoon, Younghyoun [2 ]
Xie, Yuanyuan [1 ]
Shim, Hyunsuk [2 ,3 ]
Bai, Renren [1 ]
机构
[1] Zhejiang Univ Technol, Coll Pharmaceut Sci, 18 Chaowang Rd, Hangzhou 310014, Zhejiang, Peoples R China
[2] Emory Univ, Sch Med, Dept Radiat Oncol, 1701 Uppergate Dr,C5018, Atlanta, GA 30322 USA
[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
基金
中国国家自然科学基金;
关键词
CXCR4/CXCL12; axis; Amide-sulfamide derivatives; Structural modification; Anti-tumor metastatic activity; CXCR4; POTENT; AMINES; ANTAGONISTS; CXCL12; DESIGN;
D O I
10.1016/j.ejmech.2019.111823
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Breast cancer is the most frequently diagnosed malignancy and the second common cause of death in women worldwide. High mortality in breast cancer is frequently associated with metastatic progression rather than the primary tumor itself. It has been recently identified that the CXCR4/CXCL12 axis plays a pivotal role in breast cancer metastasis, especially in directing metastatic cancer cells to CXCL12-riched organs and tissues. Herein, taking the amide-sulfamide as the lead structure, the second-round structural modifications to the sulfamide structure were performed to obtain more active CXCR4 modulators against tumor metastasis. Both in vivo and in vitro experiments illustrated that compound he possessed potent CXCR4 binding affinity, excellent anti-metastatic and anti-angiogenetic activity against breast cancer. More importantly, in a mouse breast cancer lung metastasis model, compound Me exerted a significant inhibitory effect on breast cancer metastasis. Taken together, all these positive results demonstrated that developing of CXCR4 modulators is a promising strategy to mediate breast cancer metastasis. (C) 2019 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] CXCL12/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis
    Mortezaee, Keywan
    LIFE SCIENCES, 2020, 249
  • [32] Targeting the CXCL12/CXCR4 pathway to reduce radiation treatment side effects
    Chaudary, Naz
    Hill, Richard P.
    Milosevic, Michael
    RADIOTHERAPY AND ONCOLOGY, 2024, 194
  • [33] Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists
    Mamoru Morimoto
    Yoichi Matsuo
    Shuji Koide
    Ken Tsuboi
    Tomoya Shamoto
    Takafumi Sato
    Kenta Saito
    Hiroki Takahashi
    Hiromitsu Takeyama
    BMC Cancer, 16
  • [34] Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis
    Conley-LaComb, M. Katie
    Semaan, Louie
    Singareddy, Rajareddy
    Li, Yanfeng
    Heath, Elisabeth I.
    Kim, Seongho
    Cher, Michael L.
    Chinni, Sreenivasa R.
    MOLECULAR CANCER, 2016, 15
  • [35] CXCL12/CXCR4 axis induces proliferation and invasion in human endometrial cancer
    Liu, Pingping
    Long, Ping
    Huang, Yu
    Sun, Fengyi
    Wang, Zhenyan
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2016, 8 (04): : 1719 - 1729
  • [36] The biological role of the CXCL12/CXCR4 axis in esophageal squamous cell carcinoma
    Wu, Xianxian
    Zhang, Hongdian
    Sui, Zhilin
    Wang, Yang
    Yu, Zhentao
    CANCER BIOLOGY & MEDICINE, 2021, 18 (02) : 401 - 410
  • [37] Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists
    Morimoto, Mamoru
    Matsuo, Yoichi
    Koide, Shuji
    Tsuboi, Ken
    Shamoto, Tomoya
    Sato, Takafumi
    Saito, Kenta
    Takahashi, Hiroki
    Takeyama, Hiromitsu
    BMC CANCER, 2016, 16
  • [38] Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis
    M. Katie Conley-LaComb
    Louie Semaan
    Rajareddy Singareddy
    Yanfeng Li
    Elisabeth I. Heath
    Seongho Kim
    Michael L. Cher
    Sreenivasa R. Chinni
    Molecular Cancer, 15
  • [39] Allosteric modulation of the CXCR4:CXCL12 axis by targeting receptor nanoclustering via the TMV-TMVI domain
    Garcia-Cuesta, Eva M.
    Martinez, Pablo
    Selvaraju, Karthik
    Ulltjarn, Gabriel
    Pozo, Adrian Miguel Gomez
    D'Agostino, Gianluca
    Gardeta, Sofia
    Quijada-Freire, Adriana
    Gabella, Patricia Blanco
    Roca, Carlos
    Hoyo, Daniel del
    Jimenez-Saiz, Rodrigo
    Garcia-Rubia, Alfonso
    Palacios, Blanca Soler
    Lucas, Pilar
    Ayala-Bueno, Rosa
    Acerete, Noelia Santander
    Carrasco, Yolanda
    Sorzano, Carlos Oscar
    Martinez, Ana
    Campillo, Nuria E.
    Jensen, Lasse D.
    Frade, Jose Miguel Rodriguez
    Santiago, Cesar
    Mellado, Mario
    ELIFE, 2024, 13
  • [40] Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention
    Zheng, Ning
    Chen, Jiahang
    Li, Tao
    Liu, Weiqun
    Liu, Jian
    Chen, Hongning
    Wang, Jichuang
    Jia, Lee
    MOLECULAR CARCINOGENESIS, 2017, 56 (08) : 1896 - 1908